Trial Profile

Exenatide (Byetta) Vs Pramlintide (Symlin): Role in Post-Prandial Hyperglycemia.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 Jul 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Exenatide (Primary) ; Pramlintide (Primary) ; Insulin
Indications Type 1 diabetes mellitus
Focus Therapeutic Use

Most Recent Events

13 Jun 2017 Status changed from recruiting to completed, based on the results presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
08 Dec 2010 Additional lead trial centre/investigator identified as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com